Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...7576777879808182838485...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances. (Pubmed Central) -  Sep 14, 2021   
    Recently, it has been reported that using the immune checkpoint inhibitors atezolizumab (anti-PDL1 antibody) and bevacizumab (anti-VEGF antibody) leads to longer overall survival of unresectable cases, when compared with the use of sorafenib...In this review, we describe our phase I/II clinical trials of peptide vaccines targeting GPC3 in HCC and discuss the potential of peptide vaccines targeting common cancer antigens that are highly expressed in HCC, such as WT-I, AFP, ROBO1, and FOXM1. Further, we introduce recent cancer vaccines targeting neoantigens, which have attracted attention in recent times, as well as present our preclinical studies, the results of which might aid to initiate a neoantigen vaccine clinical trial, which would be the first of its kind in Japan.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Retrospective data, Journal:  Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma. (Pubmed Central) -  Sep 12, 2021   
    Further, we introduce recent cancer vaccines targeting neoantigens, which have attracted attention in recent times, as well as present our preclinical studies, the results of which might aid to initiate a neoantigen vaccine clinical trial, which would be the first of its kind in Japan. Rechallenge treatment with lenvatinib after ramucirumab can be effective, and may be a treatment option for HCC in cases wherein the disease progressed after an initial response to lenvatinib treatment.
  • ||||||||||  lenvatinib / Generic mfg.
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Beyond Chemotherapy, PD-1, and HER-2: Novel Targets for Gastric and Esophageal Cancer. (Pubmed Central) -  Sep 11, 2021   
    Ultimately, exploiting the oncogenic tendencies of these potential biomarkers creates an opportunity for precise treatment and improved prognosis for these cancers. Lastly, research aimed toward reversing PD-1 antibodies resistance by combining it with other novel agents or other treatment modalities is underway in order to expand existing treatment options for this patient population.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  RET Inhibitors in Non-Small-Cell Lung Cancer. (Pubmed Central) -  Sep 11, 2021   
    More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy rates and good tolerability and they were approved for the treatment of patients with metastatic RET fusion-positive NSCLC on the bases of the results of phase II studies. Two ongoing phase III clinical trials are currently comparing selpercatinib or pralsetinib to standard first line treatments and will definitively establish their efficacy in RET-positive NSCLC patients.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Review, Journal, IO biomarker:  ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. (Pubmed Central) -  Sep 11, 2021   
    ALBI grade also predicts survival, toxicity and post-procedural liver failure in patients treated with transarterial chemoembolisation, radioembolisation, external beam radiotherapy as well as multi-kinase inhibitors (sorafenib, lenvatinib, cabozantinib, regorafenib) and immune checkpoint inhibitor therapy. In this review, we summarise the body of evidence surrounding the role of ALBI grade as a biomarker capable of optimising patient selection and therapeutic sequencing in HCC.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue. (Pubmed Central) -  Sep 10, 2021   
    In this review, we summarized the effects and adverse events of multikinase and selective RET inhibitors and the various diagnostic techniques for RET gene fusion. In the perspective part, we focused on the unsolved issues on treatment for RET fusion-positive lung cancer and future developments.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Opdivo (nivolumab) / Ono Pharma, BMS, Entyvio (vedolizumab) / Takeda
    Establishing Upper GI Toxicity Remission With Vedolizumab Maintenance Therapy While Resuming Immune Checkpoint Inhibitor (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_2933;    
    Patient D developed diarrhea, hematochezia and abdominal pain while on sitravatinib, nivolumab and ipilimumab, and was confirmed to have both upper and lower GI tract inflammation...2) These cases highlight an effective management strategy of vedolizumab maintenance for ICI related upper GI toxicity with ICI resumption. 3) Further prospective large-scale studies are still required to assess the efficacy of this treatment strategy.Figure: A, B) Patient A-Diffuse moderately congested gastric mucosa with friable exudates.C, D) Patient A- Follow up endoscopy reveals improvement in gastric mucosa.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Hepatocellular Carcinoma With Bilateral Adrenal Metastasis (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_2783;    
    Sorafenib has been used for this stage of HCC in the past, however the REFLECT trials have shown Lenvatinib to be non-inferior in efficacy and has a manageable tolerability profile. Considering the significant improvements in response rate, progression-free survival, and time to progression, Lenvatinib was chosen for the patient.Figure: CT Abdomen with bilateral Adrenal gland metastases (white arrows)
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Rare Case of Skull Metastasis From Recurrent Hepatocellular Carcinoma (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_1016;    
    As skull metastases from recurrent HCC are rare, identifying those patients at highest risk for HCC recurrence and surveillance protocols could allow for closer follow up and earlier detection of potential recurrences.Figure: Figure 1. MRI brain showing evidence of central occipital bone lesion (arrow).
  • ||||||||||  tenofovir disoproxil fumarate / Generic mfg., lenvatinib / Generic mfg.
    Abscess or Metastasis? Hepatocellular Carcinoma Metastatic to the Spine Presenting as an Epidural Abscess (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_245;    
    He completed 10 radiation treatments prior to discharge and was set up to complete a 28 day cycle of lenvatinib chemotherapy...Although the combination of surgery and medical management was shown to have the longest survival rates, the study was not able to determine the improvement in patient quality of life or the rate of prevention of complete paralysis with the goal of preserving ambulatory status.Figure: A: Triple phase CT of the abdomen demonstrating diffuse involvement of HCC. B: T2 MRI demonstrating T11-L1 posterior extradural mass.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Clinical, PK/PD data, Journal, Adverse events:  Current treatment options for HCC: from pharmacokinetics to efficacy and adverse events in liver cirrhosis. (Pubmed Central) -  Sep 8, 2021   
    The new scenario of systemic HCC therapy includes more active drugs with different metabolic pathways and different liver adverse events. Clinical and pharmacological studies providing more data on the safety of these molecules are urgently needed.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma. (Pubmed Central) -  Sep 8, 2021   
    A liquid chromatography tandem mass spectrometry method for the analysis of ten kinase inhibitors (afatinib, axitinib, bosutinib, cabozantinib, dabrafenib, lenvatinib, nilotinib, osimertinib, ruxolitinib, and trametinib) in human serum and plasma for the application in daily clinical routine has been developed and validated according to the US Food and Drug Administration and European Medicines Agency validation guidelines for bioanalytical methods...The rapid and sensitive assay ensures high throughput and was successfully applied to monitor concentrations of kinase inhibitors in patients. Graphical abstract.
  • ||||||||||  lenvatinib / Generic mfg.
    Preclinical, Journal:  Alkaloidal extract from Carica papaya seeds ameliorates CCl-induced hepatocellular carcinoma in rats. (Pubmed Central) -  Sep 3, 2021   
    These rats were put into five groups of 10; Carica papaya alkaloidal extract [(CPAE) (50, 100, and 200 mg/kg), Lenvatinib (4 mg/kg)], 1% dimethyl sulphoxide (DMSO), and 2 untreated groups (control and model)...The CPAE (100 and 200 mg/kg) further reduced bleeding time, improved prothrombin time and restored platelet count (p < 0.01) compared to the model. The CPAE (200 mg/kg) again significantly (p < 0.0001) reduced serum alpha-fetoprotein levels compared to the model group and prevented the establishment of HCC in rats when concerrently administered with CCl in 16 weeks prophylactic study.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Post-Marketing Surveillance of Lenvima in Korean Patients (clinicaltrials.gov) -  Sep 2, 2021   
    P=N/A,  N=3000, Recruiting, 
    Patients with advanced kidney cancer who had received other previous treatments experienced a clearly clinically important improvement in quality survival time when treated with lenvatinib plus everolimus compared to everolimus alone. Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Apr 2021 --> Sep 2021
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    New P2/3 trial, Metastases:  ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov) -  Sep 1, 2021   
    P2/3,  N=150, Not yet recruiting, 
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Trial completion date, Trial primary completion date, Tumor mutational burden, IO biomarker, Metastases:  JS001-027-III-HCC: Phase III Study of Toripalimab?JS001? Combined With Lenvatinib for Advanced HCC (clinicaltrials.gov) -  Sep 1, 2021   
    P3,  N=519, Recruiting, 
    Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Apr 2021 --> Sep 2021 Trial completion date: Aug 2024 --> Jan 2025 | Trial primary completion date: May 2024 --> Aug 2023
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, Metastases:  MK-3475-A70: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer (clinicaltrials.gov) -  Sep 1, 2021   
    P2,  N=35, Not yet recruiting, 
    The evidence of HRQOL benefits in clinically relevant domains support the use of lenvatinib compared with sorafenib to delay functional deterioration in advanced hepatocellular carcinoma. Initiation date: Jul 2021 --> Oct 2021
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Journal, IO biomarker:  Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells. (Pubmed Central) -  Aug 31, 2021   
    Trametinib, an inhibitor of the extracellular signal-regulated kinase (ERK) kinase MEK, also activated IFNγ/STAT1 signaling and increased HLA-I expression, whereas the phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib did not...Sorafenib, lenvatinib, and cabozantinib also showed the same effects as regorafenib, while regorafenib had most potent effects on HLA-I expression, possibly dependent on its stronger inhibitory activity against the MEK/ERK pathway. These results support the clinical combination of TKIs with immunotherapy for the treatment of HCC.
  • ||||||||||  Zydelig (idelalisib) / Gilead, Sutent (sunitinib) / Pfizer
    Journal:  Impact of Selected Small-Molecule Kinase Inhibitors on Lipid Membranes. (Pubmed Central) -  Aug 29, 2021   
    In this context, experimental studies on lipid membranes are necessary to (i) identify drugs that may disturb membranes and (ii) characterize drug-membrane interactions on a molecular level. Such knowledge is important for understanding the efficacy and potential side effects of respective drugs.
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, Journal:  Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. (Pubmed Central) -  Aug 26, 2021   
    The most common treatment administered was lenvatinib plus anti-PD-1 antibody and transarterial chemoembolization, and the median time span from systemic therapy to surgery was 3.2 (IQR, 2.8-6.2) months...Stereotactic therapy is a feasible conversion therapy for HCC patients with extrahepatic metastases to become resectable. This is the first study to analyse therapeutic outcomes of patients receiving these therapies for HCC with extrahepatic metastases.